Santen Pharmaceutical (Taiwan) Co., LTD clinical trials
A country office of Santen Pharmaceutical Co., Ltd.
The registry lists 2 studies whose lead sponsor is Santen Pharmaceutical (Taiwan) Co., LTD. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 31, 2022.
Registry sponsor names on this page
- Santen Pharmaceutical (Taiwan) Co., LTD2 studies
Something wrong with this grouping? Tell us on the Santen Pharmaceutical Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Santen Pharmaceutical Co., Ltd. studies →
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World SettingCompletedNCT04828057
Sponsor listed in the registry: Santen Pharmaceutical (Taiwan) Co., LTD
- Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)CompletedNCT04737928Not applicable
Sponsor listed in the registry: Santen Pharmaceutical (Taiwan) Co., LTD